AstraZeneca Buys Fusion in Potential $2B Deal, Joins Radiopharma Buying Spree
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.